BACKGROUND: Community-wide impact of pneumococcal conjugate vaccines (PCV) is conferred by reductions in vaccine-type nasopharyngeal carriage. We evaluated the impact of PCV13 on carriage of PCV13-specific types (1, 3, 5, 6A, 7F and 19A) and 6C among American Indians. METHODS: A nasopharyngeal specimen was collected from community members of all ages between January 2010 and April 2012 (3 months before and 24 months after PCV13 introduction). Pneumococci were isolated by culture and serotyped using antisera. Monthly carriage prevalence and PCV13 coverage were calculated to identify the timing of vaccine impact relative to PCV13 introduction. Prevalence ratios (PRs) were used to compare PCV13-specific carriage before and in years 1 and 2 of PCV13 use. Coverage was calculated according to age and number of doses received. RESULTS: 6645 participants (2859 <5 years and 3786 ≥5 years of age) provided 6628 specimens. A decline in PCV13-specific and type 6C carriage among children <5 years of age was observed 9 and 15 months after PCV13 introduction, respectively. Among underimmunized children, a decline in PCV13-specific carriage was observed 11 months after PCV13 introduction, when coverage in the community reached 58%. In year 2 of PCV13 use, PCV13-specific and 6C carriage were reduced by 60% and 70%, respectively (PCV13 specific: PR = 0.4, P < 0.001; 6C: PR = 0.3, P < 0.001) among children <5 years of age. The reduction in PCV13-specific carriage among those 5 to <8 years and 18+ years of age in year 2 of PCV13 use was not statistically significant. CONCLUSIONS: PCV13 reduced PCV13-specific and 6C carriage among children <5 years of age. Low pre-PCV13 carriage prevalence of PCV13-specific types limited confirming this reduction for adults.
BACKGROUND: Community-wide impact of pneumococcal conjugate vaccines (PCV) is conferred by reductions in vaccine-type nasopharyngeal carriage. We evaluated the impact of PCV13 on carriage of PCV13-specific types (1, 3, 5, 6A, 7F and 19A) and 6C among American Indians. METHODS: A nasopharyngeal specimen was collected from community members of all ages between January 2010 and April 2012 (3 months before and 24 months after PCV13 introduction). Pneumococci were isolated by culture and serotyped using antisera. Monthly carriage prevalence and PCV13 coverage were calculated to identify the timing of vaccine impact relative to PCV13 introduction. Prevalence ratios (PRs) were used to compare PCV13-specific carriage before and in years 1 and 2 of PCV13 use. Coverage was calculated according to age and number of doses received. RESULTS: 6645 participants (2859 <5 years and 3786 ≥5 years of age) provided 6628 specimens. A decline in PCV13-specific and type 6C carriage among children <5 years of age was observed 9 and 15 months after PCV13 introduction, respectively. Among underimmunized children, a decline in PCV13-specific carriage was observed 11 months after PCV13 introduction, when coverage in the community reached 58%. In year 2 of PCV13 use, PCV13-specific and 6C carriage were reduced by 60% and 70%, respectively (PCV13 specific: PR = 0.4, P < 0.001; 6C: PR = 0.3, P < 0.001) among children <5 years of age. The reduction in PCV13-specific carriage among those 5 to <8 years and 18+ years of age in year 2 of PCV13 use was not statistically significant. CONCLUSIONS: PCV13 reduced PCV13-specific and 6C carriage among children <5 years of age. Low pre-PCV13 carriage prevalence of PCV13-specific types limited confirming this reduction for adults.
Authors: Matthew D Snape; Chaam L Klinger; Elvis D Daniels; Tessa M John; Helen Layton; Llinos Rollinson; Sarah Pestridge; Sandra Dymond; Eva Galiza; Susan Tansey; Daniel A Scott; Sherryl A Baker; Thomas R Jones; Ly-Mee Yu; William C Gruber; Emilio A Emini; Saul N Faust; Adam Finn; Paul T Heath; Andrew J Pollard Journal: Pediatr Infect Dis J Date: 2010-12 Impact factor: 2.129
Authors: Ron Dagan; Christine Juergens; James Trammel; Scott Patterson; David Greenberg; Noga Givon-Lavi; Nurith Porat; Alejandra Gurtman; William C Gruber; Daniel A Scott Journal: J Infect Dis Date: 2014-10-29 Impact factor: 5.226
Authors: Pauline A Waight; Nicholas J Andrews; Shamez N Ladhani; Carmen L Sheppard; Mary P E Slack; Elizabeth Miller Journal: Lancet Infect Dis Date: 2015-03-20 Impact factor: 25.071
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071
Authors: Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson Journal: JAMA Date: 2007-04-25 Impact factor: 56.272
Authors: George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger Journal: Vaccine Date: 2007-02-21 Impact factor: 3.641
Authors: Lindsay R Grant; Sarah E O'Brien; Polly Burbidge; Mitch Haston; Marta Zancolli; Lucy Cowell; Marina Johnson; Robert C Weatherholtz; Raymond Reid; Mathuram Santosham; Katherine L O'Brien; David Goldblatt Journal: PLoS One Date: 2013-09-23 Impact factor: 3.240
Authors: Catherine G Sutcliffe; Lindsay R Grant; Emily Cloessner; Keith P Klugman; Jorge E Vidal; Raymond Reid; Janene Colelay; Robert C Weatherholtz; Sopio Chochua; Michael R Jacobs; Mathuram Santosham; Katherine L O'Brien; Laura L Hammitt Journal: Am J Epidemiol Date: 2019-12-31 Impact factor: 4.897
Authors: Seyi D Eletu; Carmen L Sheppard; Elizabeth Thomas; Kenneth Smith; Priya Daniel; David J Litt; Wei Shen Lim; Norman K Fry Journal: Clin Vaccine Immunol Date: 2017-12-05
Authors: Ki Wook Yun; Eun Hwa Choi; Hoan Jong Lee; Jin Han Kang; Kyung-Hyo Kim; Dong Soo Kim; Yae-Jean Kim; Byung Wook Eun; Sung Hee Oh; Hye-Kyung Cho; Young Jin Hong; Kwang Nam Kim; Nam Hee Kim; Yun-Kyung Kim; Hyunju Lee; Taekjin Lee; Hwang Min Kim; Eun Young Cho; Chun Soo Kim; Su Eun Park; Chi Eun Oh; Dae Sun Jo; Young Youn Choi; Jina Lee Journal: BMC Infect Dis Date: 2018-06-08 Impact factor: 3.090
Authors: Taj Azarian; Lindsay R Grant; Brian J Arnold; Laura L Hammitt; Raymond Reid; Mathuram Santosham; Robert Weatherholtz; Novalene Goklish; Claudette M Thompson; Stephen D Bentley; Katherine L O'Brien; William P Hanage; Marc Lipsitch Journal: PLoS Pathog Date: 2018-04-04 Impact factor: 6.823
Authors: Eileen M Dunne; Catherine Satzke; Felisita T Ratu; Eleanor F G Neal; Laura K Boelsen; Silivia Matanitobua; Casey L Pell; Monica L Nation; Belinda D Ortika; Rita Reyburn; Kylie Jenkins; Cattram Nguyen; Katherine Gould; Jason Hinds; Lisi Tikoduadua; Joseph Kado; Eric Rafai; Mike Kama; E Kim Mulholland; Fiona M Russell Journal: Lancet Glob Health Date: 2018-12 Impact factor: 26.763
Authors: Jocelyn Chan; Jana Y R Lai; Cattram D Nguyen; Keoudomphone Vilivong; Eileen M Dunne; Audrey Dubot-Pérès; Kimberley Fox; Jason Hinds; Kerryn A Moore; Monica L Nation; Casey L Pell; Anonh Xeuatvongsa; Manivanh Vongsouvath; Paul N Newton; Kim Mulholland; Catherine Satzke; David A B Dance; Fiona M Russell Journal: BMJ Glob Health Date: 2021-06
Authors: Jocelyn Chan; Cattram D Nguyen; Jana Y R Lai; Eileen M Dunne; Ross Andrews; Christopher C Blyth; Siddhartha Datta; Kim Fox; Rebecca Ford; Jason Hinds; Sophie La Vincente; Deborah Lehmann; Ruth Lim; Tuya Mungun; Paul N Newton; Rattanaphone Phetsouvanh; Willam S Pomat; Anonh Xeuatvongsa; Claire von Mollendorf; David A B Dance; Catherine Satzke; Kim Muholland; Fiona M Russell Journal: BMJ Open Date: 2018-05-18 Impact factor: 2.692